Bill banning sale pets on sidewalks, parking lots signed into law
ATLANTA (WSAV) — A bill making it illegal to sell dogs, cats and rabbits on roadsides, parks and parking lots was signed into law on Friday.
Governor Brian Kemp has officially signed House Bill 331 into law. Advocates have called the bill a victory for efforts to combat backyard breeding, puppy mills and illicit pet sales.
Dogs, cats and domestic rabbits can't be sold, exchanged or advertised for commercial purposes on any roadside, public right of way, parkway, median, public or commercial parking lot or sidewalk, park, recreation area, fair, transient or seasonal flea market or similar transient market or outdoor location, the bill said.
'Puppy mills frequently sell on roadsides and parking lots to prevent the public from seeing the oftentimes cruel and dire conditions these pets are bred in,' said Senior Director of Advocacy and Network Partners, Best Friends Animal Society Laura Donahue. 'I'm extremely grateful to Governor Kemp for taking a stand for Georgia's pets.'
Individuals who violate the law could face fines up to $100 for the first offense, $250 for the second and $500 for the third and subsequent offenses. Corporations would face a fine up to $1,000, between 200-500 hours of community service or both.
Additionally, each animal sold would represent a separate offense.
'I backed the roadside sales element because every Georgians' pet deserves a safe and loving home,' a sponsor of the bill, Rep. Beth Camp (R) said. 'By ending roadside and parking lot sales, we're protecting our neighbors, our families, and our community's most vulnerable animals.'
Read the full bill here:
Georgia-2025-HB331-EnrolledDownload
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Donaldson's Q3 Earnings Beat Estimates, Sales Increase Y/Y
Donaldson Company, Inc. DCI reported third-quarter fiscal 2025 (ended April 30, 2025) adjusted earnings of 99 cents per share, which beat the Zacks Consensus Estimate of 95 cents. The bottom line increased 7.6% year over year. Total revenues of $940.1 million beat the Zacks Consensus Estimate of $939 million. The top line increased 1.3% year over year (up 1.6% at constant currency). (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Region-wise, Donaldson's net sales in the United States/Canada increased 0.9% year over year. The metric decreased 0.6% year over year in Europe, the Middle East and Africa, and increased 2.3% in Latin America. Also, net sales in the Asia Pacific improved 5.2%.Donaldson reports revenues under three segments, namely Mobile Solutions, Industrial Solutions and Life Sciences.A brief snapshot of segmental sales is provided Mobile Solutions segment's (accounting for 62% of net sales) sales were $582.6 million, indicating a year-over-year decline of 0.4%. Sales fell 8.3% in Off-Road and 24.5% in On-Road businesses during the quarter. Aftermarket sales improved 3.3% year over generated from the Industrial Solutions segment (30.1%) were $283.3 million, up 5.3% year over year. Industrial Filtration Solutions' sales increased 1.4% year over year. Sales growth of 27.1% in the Aerospace and Defense businesses also aided the generated from the Life Sciences segment (7.9%) were $74.2 million, up 0.7% year over year. The results benefited from continued volume growth in the Disk Drive business. Donaldson Company, Inc. price-consensus-eps-surprise-chart | Donaldson Company, Inc. Quote In the fiscal third quarter, Donaldson's cost of sales increased 3.4% year over year to $618.2 million. Gross profit declined 2.5% to $321.9 million. The gross margin of 34.2% declined 140 basis points, due to higher manufacturing expenses rose 25.7% year over year to $234.5 million. Operating profit decreased 39.1% to $87.4 million. The operating margin was 9.3%, down 620 bps year over effective tax rate was 33.6% compared with 21.2% in the year-ago quarter. Exiting the fiscal third quarter, Donaldson's cash and cash equivalents were $178.5 million compared with $232.7 million in the fourth quarter of fiscal 2024. Long-term debt was $638.8 million compared with $483.4 million in the fourth quarter of fiscal the first nine months of fiscal 2025, the company generated net cash of $251.0 million from operating activities, indicating a decrease of 31.5% year over year. Capital expenditure (net) totaled $58.6 million compared with $65.8 million in the year-ago fiscal period. Free cash flow decreased 36% to $192.4 million. In the same time frame, management repaid a long-term debt of $65 used $272.2 million to repurchase stocks and $96.9 million to pay out dividends during the first nine months of fiscal 2025. For fiscal 2025 (ending July 2025), Donaldson expects adjusted earnings per share to be in the range of $3.64-$3.70 compared with $3.42 in fiscal 2024. Sales are anticipated to increase 1- 3% from the fiscal 2024 level. Positive pricing is projected to have an accretive impact of 1%.On a segmental basis, Mobile Solutions' sales are expected to be flat to increase 2% from the fiscal 2024 level. Industrial Solutions' sales are envisioned to jump in the range of 2-4% from the year-ago figure. The company forecasts its Life Sciences segment's sales to increase in the high single-digit expenses are predicted to be approximately $23 million, while other income is projected to be in the range of $18-$20 million. The effective tax rate is anticipated to be between 23% and 24%.Capital expenditure is expected to be between $75 million and $90 million. Free cash flow conversion is anticipated to be in the range of 80-90%. The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. AZZ Inc. AZZ came out with quarterly earnings of 98 cents per share in the second quarter of fiscal 2025 (ended February 2025), beating the Zacks Consensus Estimate of 95 cents. This compares with earnings of 93 cents per share a year reported revenues of $351.9 million, missing the consensus estimate by 3.8%. This compares with year-ago revenues of $366.5 million. Valmont Industries VMI reported revenues of $969.3 million in the first quarter of 2025, declining 0.9% on a year-over-year basis. Earnings per share of $4.32 remained flat year over reported revenues compare with the Zacks Consensus Estimate of $975.6 million. The company delivered an earnings surprise of 1.89%, with the consensus estimate being $4.24 per plc PNR came out with quarterly earnings of $1.11 per share in the first quarter of 2025, beating the Zacks Consensus Estimate of $1.01. This compares with earnings of 94 cents per share a year reported revenues of $1.01 billion for the quarter, surpassing the consensus estimate by 2.7%. This compares with year-ago revenues of $1.02 billion. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Valmont Industries, Inc. (VMI) : Free Stock Analysis Report AZZ Inc. (AZZ) : Free Stock Analysis Report Donaldson Company, Inc. (DCI) : Free Stock Analysis Report Pentair plc (PNR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
8 minutes ago
- Yahoo
HealthEquity Stock Gains as Q1 Earnings Beat Estimates, Revenues Up Y/Y
HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of 97 cents for first-quarter fiscal 2026, surpassing the Zacks Consensus Estimate by 19.8%. The bottom line improved 21.3% on a year-over-year basis. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) GAAP EPS in the fiscal first quarter was 61 cents, up 84.8% compared with the year-ago quarter's EPS. Shares of HQY were up 5.8% in after-market trading following the earnings call. In the fiscal first quarter, the company generated revenues of $330.8 million, which beat the Zacks Consensus Estimate by 3%. The top line improved 15% from the prior-year quarter. As of April 30, 2025, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 9.9 million, up 9% year over year. HealthEquity reported 770,000 HSAs with investments as of April 30, 2025, up 16% year over year. Total accounts, as of April 30, 2025, were 17.1 million, up 6.9% year over year. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs), up 4.3% year over year. Total HSA assets were $31.3 billion at the end of April 30, 2025, up 15% year over year. This included $17.1 billion of HSA cash (up 7.5% year over year) and $14.2 billion of HSA investments (up 24.6% year over year). This figure compares to our fiscal first-quarter HSA cash and HSA investments projection of $18.3 billion and $13.5 billion, respectively. We had projected total HSA assets of $31.9 billion for the fiscal first quarter. Client-held funds, which are deposits held on behalf of HealthEquity's clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $0.9 billion as of April 30, 2025. HealthEquity derives revenues from three sources: Service revenues, Custodial revenues, and Interchange revenues. Service revenues totaled $119.8 million in the quarter, up 1.3% year over year. This reflected a higher number of HSAs and invested HSA Assets. This figure compares favorably with our first-quarter projection of $121.9 million. Custodial revenues totaled $156.5 million, up 28.6% from the year-ago period. Our projection for the fiscal first-quarter Custodial revenues was $140.4 million. Interchange revenues totaled $54.6 million, up 14.4% year over year. This figure compares favorably with our fiscal first-quarter projection of $52 million. HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote In the quarter under review, HealthEquity's gross profit rose 19.9% to $224.3 million. The gross margin expanded 270 basis points (bps) to 67.8%. We had projected the gross margin to be 63.2% in the fiscal first quarter. Sales and marketing expenses rose 10.6% to $25.9 million year over year, whereas technology and development expenses climbed 9.5% year over year to $61.4 million. General and administrative expenses decreased 33.2% year over year to $25.5 million. Total operating expenses of $141.2 million decreased 2.9% year over year. Operating profit totaled $83.1 million, improving significantly by 99.6% from the prior-year quarter. The operating margin in the quarter expanded by a huge 1060 bps to 25.1% compared with the prior-year quarter. The company exited the first quarter of fiscal 2026 with cash and cash equivalents of $287.9 million compared with $295.9 million at the end of the fourth quarter of fiscal 2025. Total debt (net of issuance costs) at the end of first-quarter fiscal 2026 was $1.06 billion, flat compared with that at the end of fourth-quarter fiscal 2025. Net cash provided by operating activities at the end of first-quarter fiscal 2026 totaled $64.7 million compared with $65.4 million a year ago. HealthEquity has reiterated its revenue and updated its EPS projections for fiscal 2026. For fiscal 2026, revenues are projected to be between $1.285 billion and $1.305 billion. The Zacks Consensus Estimate is currently pegged at $1.30 billion. Adjusted EPS is now expected to be in the range of $3.61-$3.78 as compared with the previous guidance of $3.57-$3.74. The Zacks Consensus Estimate currently stands at $3.60. HealthEquity exited first-quarter fiscal 2026 with better-than-expected results. The company witnessed solid top-line and bottom-line performances in the reported quarter. Solid growth in HSAs also drove the top line. The solid uptick in total HSA assets in the reported quarter is promising. Significant improvement in the operating and gross margins also bodes well. The company added 150,000 new HSAs during the quarter and maintained strong enterprise pipeline momentum despite macroeconomic pressures. Per management, fraud-related costs dropped significantly from $11 million in the fourth quarter of fiscal 2025 to $3 million in the reported quarter, thanks to AI-powered tools and enhanced mobile security, boosting margins and member trust. Management raised full-year guidance and reiterated confidence in further margin normalization, growth from legislative tailwinds, and strong client retention, positioning HQY for sustained growth and operational strength. However, fraud-related costs, though significantly reduced, still stood at $3 million, which management acknowledged as still elevated. While this reflects major improvement from the prior quarter's $11 million, it highlights that fraud remains a lingering operational risk. Management is targeting to bring fraud costs down to 1 basis point of total HSA assets. Currently, HealthEquity carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
12 minutes ago
- Yahoo
Paving program to upgrade Piqua streets and alleys
DAYTON, Ohio (WDTN) — A new citywide initiative will bring improvements to Piqua streets and alleys. According to the Miami Valley Today, the 2025 Pavement Program will focus on improving streets and alleys throughout Piqua, from street pavement surfacing treatments and alley resurfacing to curb ramp replacements. Alleys approved for the project have already been receiving maintenance work. The installation of new curb ramps are also in store, which will comply with the standards stated in the Americans with Disabilities Act. The ramps will be constructed from June through August at intersections and sidewalk crossings set for pavement surfacing treatments. The pavement surfacing treatments will begin in early September. Selected streets, alleys and curbs were chosen as part of the Pavement Condition Index report, which was filed by the city last year. For additional information, visit Piqua's website. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
